Association of p53 and p21 polymorphisms with prostate cancer

Cell cycle deregulation is common in human cancer. Alterations of the tumor-suppressor gene p53 and its downstream effector p21 have been indicated in the development of numerous human malignancies. Therefore, we hypothesize that the p53 codon 72 polymorphism, either on its own or in combination wit...

Full description

Saved in:
Bibliographic Details
Published in:Biomedical reports 2015-09, Vol.3 (5), p.707-714
Main Authors: SIVOŇOVÁ, MONIKA KMEŤOVÁ, VILČKOVÁ, MARTA, KLIMENT, JÁN, MAHMOOD, SILVIA, JUREČEKOVÁ, JANA, DUŠENKOVÁ, SVETLANA, WACZULÍKOVÁ, IVETA, SLEZÁK, PETER, DOBROTA, DUŠAN
Format: Article
Language:English
Subjects:
Apoptosis
Arginine
Cell cycle
cigarette smoking
Confidence intervals
Cyclin-dependent kinase inhibitor p21
Cyclin-dependent kinases
Deoxyribonucleic acid
Deregulation
DNA
Gene polymorphism
Genes
Genetic aspects
Genetic polymorphisms
GTP-binding protein
Health risk assessment
Kinases
p21
p53
p53 Protein
Pathogenesis
Physiological aspects
Polymerase chain reaction
Polymorphism
Population studies
Proline
Prostate cancer
Prostate-specific antigen
Proteins
Restriction fragment length polymorphism
Risk
Risk factors
Slovak population
Smoking
Statistical analysis
Studies
Tumor proteins
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c434t-711d8861bb6be8cd46f6b31f8d519ab938943d6ba0dac7a30b6f27ad5de1411c3
cites cdi_FETCH-LOGICAL-c434t-711d8861bb6be8cd46f6b31f8d519ab938943d6ba0dac7a30b6f27ad5de1411c3
container_end_page 714
container_issue 5
container_start_page 707
container_title Biomedical reports
container_volume 3
creator SIVOŇOVÁ, MONIKA KMEŤOVÁ
VILČKOVÁ, MARTA
KLIMENT, JÁN
MAHMOOD, SILVIA
JUREČEKOVÁ, JANA
DUŠENKOVÁ, SVETLANA
WACZULÍKOVÁ, IVETA
SLEZÁK, PETER
DOBROTA, DUŠAN
description Cell cycle deregulation is common in human cancer. Alterations of the tumor-suppressor gene p53 and its downstream effector p21 have been indicated in the development of numerous human malignancies. Therefore, we hypothesize that the p53 codon 72 polymorphism, either on its own or in combination with p21 (C98A and C70T) polymorphisms, modifies the risk of prostate cancer within the Slovak population, and no previous studies have investigated these gene-gene interactions in the pathogenesis of prostate cancer in the Slovak population. Polymerase chain reaction-restriction fragment length polymorphism was used to determine the p53 and p21 genotypes in subjects comprising 300 prostate cancer patients and 446 healthy individuals. These 3 polymorphisms individually did not correlate with the prostate cancer risk. Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P0.05). A decreased risk of prostate cancer association with the p21 C98A CA genotype (OR=0.58; 95% CI, 0.36-0.93; P
doi_str_mv 10.3892/br.2015.496
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4576486</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A432895372</galeid><sourcerecordid>A432895372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-711d8861bb6be8cd46f6b31f8d519ab938943d6ba0dac7a30b6f27ad5de1411c3</originalsourceid><addsrcrecordid>eNptkdtLHDEUxkOpVLE-9b0M9KVQZpv7JA8KW_EGgiDtc8ht3MhMMiazFv_7ZlHXKuZAEpLf-U5OPgC-ILggQuKfJi8wRGxBJf8A9jCkspWU4o_bPaG74KCUW1iH7CBm4hPYxZxCxhjcA4fLUpINeg4pNqlvJkYaHV0zYdRMaXgYU55WoYyl-RvmVTPlVGY9-8bqaH3-DHZ6PRR_8LTugz-nJ7-Pz9vLq7OL4-Vla2v9ue0QckJwZAw3XlhHec8NQb1wDEltZO2EEseNhk7bThNoeI877ZjziCJkyT44etSd1mb0zvo4Zz2oKYdR5weVdFCvb2JYqZt0ryjrOBW8Cnx_Esjpbu3LrMZQrB8GHX1aF4UE5hx3iHQV_fYGvU3rHGt7CkkCJcV1fqFu9OBViH2qde1GVC0pwUIy0uFKLd6hajg_Bpui70M9f5Xw4zHB1o8u2ffbHhFUG8OVyWpjuKqGV_rr_9-yZZ_tfXllmaqpwaWyZX5dt7DGRuYfHiGvgA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1930942930</pqid></control><display><type>article</type><title>Association of p53 and p21 polymorphisms with prostate cancer</title><source>PubMed Central</source><creator>SIVOŇOVÁ, MONIKA KMEŤOVÁ ; VILČKOVÁ, MARTA ; KLIMENT, JÁN ; MAHMOOD, SILVIA ; JUREČEKOVÁ, JANA ; DUŠENKOVÁ, SVETLANA ; WACZULÍKOVÁ, IVETA ; SLEZÁK, PETER ; DOBROTA, DUŠAN</creator><creatorcontrib>SIVOŇOVÁ, MONIKA KMEŤOVÁ ; VILČKOVÁ, MARTA ; KLIMENT, JÁN ; MAHMOOD, SILVIA ; JUREČEKOVÁ, JANA ; DUŠENKOVÁ, SVETLANA ; WACZULÍKOVÁ, IVETA ; SLEZÁK, PETER ; DOBROTA, DUŠAN</creatorcontrib><description>Cell cycle deregulation is common in human cancer. Alterations of the tumor-suppressor gene p53 and its downstream effector p21 have been indicated in the development of numerous human malignancies. Therefore, we hypothesize that the p53 codon 72 polymorphism, either on its own or in combination with p21 (C98A and C70T) polymorphisms, modifies the risk of prostate cancer within the Slovak population, and no previous studies have investigated these gene-gene interactions in the pathogenesis of prostate cancer in the Slovak population. Polymerase chain reaction-restriction fragment length polymorphism was used to determine the p53 and p21 genotypes in subjects comprising 300 prostate cancer patients and 446 healthy individuals. These 3 polymorphisms individually did not correlate with the prostate cancer risk. Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P&lt;0.05] for subjects carrying the p53 codon 72 arginine (Arg)/proline (Pro)+Pro/Pro and p21 C98A CA genotypes compared to the combined reference genotypes p53 codon 72 Arg/Arg and p21 C98A CC. Neither the p53 genotypes nor the p21 genotypes showed statistically significant differences in Gleason score or serum prostate-specific antigen levels (P&gt;0.05). A decreased risk of prostate cancer association with the p21 C98A CA genotype (OR=0.58; 95% CI, 0.36-0.93; P&lt;0.05) in non-smokers compared to the non-smokers with the p21 C98A CC genotype was observed. Smokers carrying the p53 codon 72 Pro/Pro genotype were not at any significant risk of prostate cancer (OR=2.97; 95% CI, 0.51-17.15) compared to the non-smokers with the Arg/Arg genotype. Taken together, to the best of our knowledge this is the first study to show that a combination of the variant genotypes of p53 codon 72 and p21 C98A may modify the prostate cancer risk within the Slovak population.</description><identifier>ISSN: 2049-9434</identifier><identifier>EISSN: 2049-9442</identifier><identifier>DOI: 10.3892/br.2015.496</identifier><identifier>PMID: 26405550</identifier><language>eng</language><publisher>England: D.A. Spandidos</publisher><subject>Apoptosis ; Arginine ; Cell cycle ; cigarette smoking ; Confidence intervals ; Cyclin-dependent kinase inhibitor p21 ; Cyclin-dependent kinases ; Deoxyribonucleic acid ; Deregulation ; DNA ; Gene polymorphism ; Genes ; Genetic aspects ; Genetic polymorphisms ; GTP-binding protein ; Health risk assessment ; Kinases ; p21 ; p53 ; p53 Protein ; Pathogenesis ; Physiological aspects ; Polymerase chain reaction ; Polymorphism ; Population studies ; Proline ; Prostate cancer ; Prostate-specific antigen ; Proteins ; Restriction fragment length polymorphism ; Risk ; Risk factors ; Slovak population ; Smoking ; Statistical analysis ; Studies ; Tumor proteins ; Tumors</subject><ispartof>Biomedical reports, 2015-09, Vol.3 (5), p.707-714</ispartof><rights>Copyright © 2015, Spandidos Publications</rights><rights>COPYRIGHT 2015 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2015</rights><rights>Copyright © 2015, Spandidos Publications 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-711d8861bb6be8cd46f6b31f8d519ab938943d6ba0dac7a30b6f27ad5de1411c3</citedby><cites>FETCH-LOGICAL-c434t-711d8861bb6be8cd46f6b31f8d519ab938943d6ba0dac7a30b6f27ad5de1411c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576486/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576486/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26405550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SIVOŇOVÁ, MONIKA KMEŤOVÁ</creatorcontrib><creatorcontrib>VILČKOVÁ, MARTA</creatorcontrib><creatorcontrib>KLIMENT, JÁN</creatorcontrib><creatorcontrib>MAHMOOD, SILVIA</creatorcontrib><creatorcontrib>JUREČEKOVÁ, JANA</creatorcontrib><creatorcontrib>DUŠENKOVÁ, SVETLANA</creatorcontrib><creatorcontrib>WACZULÍKOVÁ, IVETA</creatorcontrib><creatorcontrib>SLEZÁK, PETER</creatorcontrib><creatorcontrib>DOBROTA, DUŠAN</creatorcontrib><title>Association of p53 and p21 polymorphisms with prostate cancer</title><title>Biomedical reports</title><addtitle>Biomed Rep</addtitle><description>Cell cycle deregulation is common in human cancer. Alterations of the tumor-suppressor gene p53 and its downstream effector p21 have been indicated in the development of numerous human malignancies. Therefore, we hypothesize that the p53 codon 72 polymorphism, either on its own or in combination with p21 (C98A and C70T) polymorphisms, modifies the risk of prostate cancer within the Slovak population, and no previous studies have investigated these gene-gene interactions in the pathogenesis of prostate cancer in the Slovak population. Polymerase chain reaction-restriction fragment length polymorphism was used to determine the p53 and p21 genotypes in subjects comprising 300 prostate cancer patients and 446 healthy individuals. These 3 polymorphisms individually did not correlate with the prostate cancer risk. Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P&lt;0.05] for subjects carrying the p53 codon 72 arginine (Arg)/proline (Pro)+Pro/Pro and p21 C98A CA genotypes compared to the combined reference genotypes p53 codon 72 Arg/Arg and p21 C98A CC. Neither the p53 genotypes nor the p21 genotypes showed statistically significant differences in Gleason score or serum prostate-specific antigen levels (P&gt;0.05). A decreased risk of prostate cancer association with the p21 C98A CA genotype (OR=0.58; 95% CI, 0.36-0.93; P&lt;0.05) in non-smokers compared to the non-smokers with the p21 C98A CC genotype was observed. Smokers carrying the p53 codon 72 Pro/Pro genotype were not at any significant risk of prostate cancer (OR=2.97; 95% CI, 0.51-17.15) compared to the non-smokers with the Arg/Arg genotype. Taken together, to the best of our knowledge this is the first study to show that a combination of the variant genotypes of p53 codon 72 and p21 C98A may modify the prostate cancer risk within the Slovak population.</description><subject>Apoptosis</subject><subject>Arginine</subject><subject>Cell cycle</subject><subject>cigarette smoking</subject><subject>Confidence intervals</subject><subject>Cyclin-dependent kinase inhibitor p21</subject><subject>Cyclin-dependent kinases</subject><subject>Deoxyribonucleic acid</subject><subject>Deregulation</subject><subject>DNA</subject><subject>Gene polymorphism</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Genetic polymorphisms</subject><subject>GTP-binding protein</subject><subject>Health risk assessment</subject><subject>Kinases</subject><subject>p21</subject><subject>p53</subject><subject>p53 Protein</subject><subject>Pathogenesis</subject><subject>Physiological aspects</subject><subject>Polymerase chain reaction</subject><subject>Polymorphism</subject><subject>Population studies</subject><subject>Proline</subject><subject>Prostate cancer</subject><subject>Prostate-specific antigen</subject><subject>Proteins</subject><subject>Restriction fragment length polymorphism</subject><subject>Risk</subject><subject>Risk factors</subject><subject>Slovak population</subject><subject>Smoking</subject><subject>Statistical analysis</subject><subject>Studies</subject><subject>Tumor proteins</subject><subject>Tumors</subject><issn>2049-9434</issn><issn>2049-9442</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNptkdtLHDEUxkOpVLE-9b0M9KVQZpv7JA8KW_EGgiDtc8ht3MhMMiazFv_7ZlHXKuZAEpLf-U5OPgC-ILggQuKfJi8wRGxBJf8A9jCkspWU4o_bPaG74KCUW1iH7CBm4hPYxZxCxhjcA4fLUpINeg4pNqlvJkYaHV0zYdRMaXgYU55WoYyl-RvmVTPlVGY9-8bqaH3-DHZ6PRR_8LTugz-nJ7-Pz9vLq7OL4-Vla2v9ue0QckJwZAw3XlhHec8NQb1wDEltZO2EEseNhk7bThNoeI877ZjziCJkyT44etSd1mb0zvo4Zz2oKYdR5weVdFCvb2JYqZt0ryjrOBW8Cnx_Esjpbu3LrMZQrB8GHX1aF4UE5hx3iHQV_fYGvU3rHGt7CkkCJcV1fqFu9OBViH2qde1GVC0pwUIy0uFKLd6hajg_Bpui70M9f5Xw4zHB1o8u2ffbHhFUG8OVyWpjuKqGV_rr_9-yZZ_tfXllmaqpwaWyZX5dt7DGRuYfHiGvgA</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>SIVOŇOVÁ, MONIKA KMEŤOVÁ</creator><creator>VILČKOVÁ, MARTA</creator><creator>KLIMENT, JÁN</creator><creator>MAHMOOD, SILVIA</creator><creator>JUREČEKOVÁ, JANA</creator><creator>DUŠENKOVÁ, SVETLANA</creator><creator>WACZULÍKOVÁ, IVETA</creator><creator>SLEZÁK, PETER</creator><creator>DOBROTA, DUŠAN</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150901</creationdate><title>Association of p53 and p21 polymorphisms with prostate cancer</title><author>SIVOŇOVÁ, MONIKA KMEŤOVÁ ; VILČKOVÁ, MARTA ; KLIMENT, JÁN ; MAHMOOD, SILVIA ; JUREČEKOVÁ, JANA ; DUŠENKOVÁ, SVETLANA ; WACZULÍKOVÁ, IVETA ; SLEZÁK, PETER ; DOBROTA, DUŠAN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-711d8861bb6be8cd46f6b31f8d519ab938943d6ba0dac7a30b6f27ad5de1411c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Apoptosis</topic><topic>Arginine</topic><topic>Cell cycle</topic><topic>cigarette smoking</topic><topic>Confidence intervals</topic><topic>Cyclin-dependent kinase inhibitor p21</topic><topic>Cyclin-dependent kinases</topic><topic>Deoxyribonucleic acid</topic><topic>Deregulation</topic><topic>DNA</topic><topic>Gene polymorphism</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Genetic polymorphisms</topic><topic>GTP-binding protein</topic><topic>Health risk assessment</topic><topic>Kinases</topic><topic>p21</topic><topic>p53</topic><topic>p53 Protein</topic><topic>Pathogenesis</topic><topic>Physiological aspects</topic><topic>Polymerase chain reaction</topic><topic>Polymorphism</topic><topic>Population studies</topic><topic>Proline</topic><topic>Prostate cancer</topic><topic>Prostate-specific antigen</topic><topic>Proteins</topic><topic>Restriction fragment length polymorphism</topic><topic>Risk</topic><topic>Risk factors</topic><topic>Slovak population</topic><topic>Smoking</topic><topic>Statistical analysis</topic><topic>Studies</topic><topic>Tumor proteins</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SIVOŇOVÁ, MONIKA KMEŤOVÁ</creatorcontrib><creatorcontrib>VILČKOVÁ, MARTA</creatorcontrib><creatorcontrib>KLIMENT, JÁN</creatorcontrib><creatorcontrib>MAHMOOD, SILVIA</creatorcontrib><creatorcontrib>JUREČEKOVÁ, JANA</creatorcontrib><creatorcontrib>DUŠENKOVÁ, SVETLANA</creatorcontrib><creatorcontrib>WACZULÍKOVÁ, IVETA</creatorcontrib><creatorcontrib>SLEZÁK, PETER</creatorcontrib><creatorcontrib>DOBROTA, DUŠAN</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Database‎ (1962 - current)</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>Biological Science Database</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biomedical reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SIVOŇOVÁ, MONIKA KMEŤOVÁ</au><au>VILČKOVÁ, MARTA</au><au>KLIMENT, JÁN</au><au>MAHMOOD, SILVIA</au><au>JUREČEKOVÁ, JANA</au><au>DUŠENKOVÁ, SVETLANA</au><au>WACZULÍKOVÁ, IVETA</au><au>SLEZÁK, PETER</au><au>DOBROTA, DUŠAN</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of p53 and p21 polymorphisms with prostate cancer</atitle><jtitle>Biomedical reports</jtitle><addtitle>Biomed Rep</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>3</volume><issue>5</issue><spage>707</spage><epage>714</epage><pages>707-714</pages><issn>2049-9434</issn><eissn>2049-9442</eissn><abstract>Cell cycle deregulation is common in human cancer. Alterations of the tumor-suppressor gene p53 and its downstream effector p21 have been indicated in the development of numerous human malignancies. Therefore, we hypothesize that the p53 codon 72 polymorphism, either on its own or in combination with p21 (C98A and C70T) polymorphisms, modifies the risk of prostate cancer within the Slovak population, and no previous studies have investigated these gene-gene interactions in the pathogenesis of prostate cancer in the Slovak population. Polymerase chain reaction-restriction fragment length polymorphism was used to determine the p53 and p21 genotypes in subjects comprising 300 prostate cancer patients and 446 healthy individuals. These 3 polymorphisms individually did not correlate with the prostate cancer risk. Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P&lt;0.05] for subjects carrying the p53 codon 72 arginine (Arg)/proline (Pro)+Pro/Pro and p21 C98A CA genotypes compared to the combined reference genotypes p53 codon 72 Arg/Arg and p21 C98A CC. Neither the p53 genotypes nor the p21 genotypes showed statistically significant differences in Gleason score or serum prostate-specific antigen levels (P&gt;0.05). A decreased risk of prostate cancer association with the p21 C98A CA genotype (OR=0.58; 95% CI, 0.36-0.93; P&lt;0.05) in non-smokers compared to the non-smokers with the p21 C98A CC genotype was observed. Smokers carrying the p53 codon 72 Pro/Pro genotype were not at any significant risk of prostate cancer (OR=2.97; 95% CI, 0.51-17.15) compared to the non-smokers with the Arg/Arg genotype. Taken together, to the best of our knowledge this is the first study to show that a combination of the variant genotypes of p53 codon 72 and p21 C98A may modify the prostate cancer risk within the Slovak population.</abstract><cop>England</cop><pub>D.A. Spandidos</pub><pmid>26405550</pmid><doi>10.3892/br.2015.496</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2049-9434
ispartof Biomedical reports, 2015-09, Vol.3 (5), p.707-714
issn 2049-9434
2049-9442
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4576486
source PubMed Central
subjects Apoptosis
Arginine
Cell cycle
cigarette smoking
Confidence intervals
Cyclin-dependent kinase inhibitor p21
Cyclin-dependent kinases
Deoxyribonucleic acid
Deregulation
DNA
Gene polymorphism
Genes
Genetic aspects
Genetic polymorphisms
GTP-binding protein
Health risk assessment
Kinases
p21
p53
p53 Protein
Pathogenesis
Physiological aspects
Polymerase chain reaction
Polymorphism
Population studies
Proline
Prostate cancer
Prostate-specific antigen
Proteins
Restriction fragment length polymorphism
Risk
Risk factors
Slovak population
Smoking
Statistical analysis
Studies
Tumor proteins
Tumors
title Association of p53 and p21 polymorphisms with prostate cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T15%3A52%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20p53%20and%20p21%20polymorphisms%20with%20prostate%20cancer&rft.jtitle=Biomedical%20reports&rft.au=SIVO%C5%87OV%C3%81,%20MONIKA%20KME%C5%A4OV%C3%81&rft.date=2015-09-01&rft.volume=3&rft.issue=5&rft.spage=707&rft.epage=714&rft.pages=707-714&rft.issn=2049-9434&rft.eissn=2049-9442&rft_id=info:doi/10.3892/br.2015.496&rft_dat=%3Cgale_pubme%3EA432895372%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c434t-711d8861bb6be8cd46f6b31f8d519ab938943d6ba0dac7a30b6f27ad5de1411c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1930942930&rft_id=info:pmid/26405550&rft_galeid=A432895372&rfr_iscdi=true